The Netherlands Cancer Institute

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this ag…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to se…

This phase 2 trial tests whether a combination of two immunotherapy drugs (ipilimumab and cemiplimab) plus targeted radiation can help people with advanced non-small cell lung cancer whose previous immunotherapy stopped working. The study enrolls 54 participants and aims to see i…

This study tests whether a special scan (SPECT/CT) can map where a head and neck tumor drains lymph fluid. If the scan shows no drainage to the opposite side of the neck, doctors can safely avoid radiating that side, reducing side effects. About 90 patients with newly diagnosed h…

This study is testing whether women with a very early, low-risk form of breast cancer called DCIS can safely avoid standard treatments like surgery and radiation. Instead, they would simply get a yearly mammogram to monitor the condition. The goal is to see if this 'active survei…

This study compares the usual 5-week radiation schedule before sarcoma surgery to a shorter 2-week course. Researchers want to see if the shorter course leads to similar wound healing and tumor control. About 168 adults with soft tissue sarcomas in the head, neck, trunk, or limbs…

This phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in 25 adults with a specific type of advanced colorectal cancer (dMMR) that cannot be surgically removed. The goal is to see if the drug can shrink the tumors enough to make surgery possible. Treatment …

This phase II trial tests three different immunotherapy combinations given before surgery to patients with high-risk clear cell kidney cancer. The goal is to see if these drugs can shrink the tumor and reduce the risk of the cancer returning. About 69 participants will receive ei…

This study aimed to test a combination of two drugs—LY3200882 and capecitabine—in people with advanced colorectal cancer that had stopped responding to chemotherapy. The goal was to see if the combination could re-sensitize tumors to treatment. However, the trial was withdrawn be…

This study tests a new way to give radiotherapy for men with intermediate-risk prostate cancer. The goal is to lower the dose to healthy parts of the prostate while boosting the dose to the tumor, using a special MRI-guided machine (MR-linac). Twenty men will take part to see if …

This study looks at whether a genetic test (BRCA1-like) can help doctors choose the best first chemotherapy for people with advanced triple-negative breast cancer. About 304 participants will receive either carboplatin-cyclophosphamide or paclitaxel, with or without the immunothe…